Qiagen NV
NYSE:QGEN

Watchlist Manager
Qiagen NV Logo
Qiagen NV
NYSE:QGEN
Watchlist
Price: 45.06 USD 0.54%
Market Cap: 10B USD
Have any thoughts about
Qiagen NV?
Write Note

Qiagen NV
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Qiagen NV
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Qiagen NV
NYSE:QGEN
Current Portion of Long-Term Debt
$555.3m
CAGR 3-Years
14%
CAGR 5-Years
50%
CAGR 10-Years
16%
No Stocks Found

Qiagen NV
Glance View

Market Cap
10B USD
Industry
Life Sciences Tools & Services

Qiagen NV, a luminary in the realm of biotechnology, navigates the intricate world of molecular diagnostics and testing with a blend of innovation and expertise. Originating in 1984 in the Netherlands, this company has grown into a formidable presence in the life sciences sector. Qiagen's journey revolves around its core mission: to enable advancements in science and healthcare by providing technologies and solutions that unlock molecular insights. At the heart of its operations lies a comprehensive portfolio of sample and assay technologies. These are critical tools for laboratories worldwide, instrumental in the isolation and preparation of nucleic acids, such as DNA and RNA. With these tools, researchers and clinicians can delve deeper into the molecular underpinnings of diseases, paving the way for breakthroughs in diagnostics and treatment. Qiagen’s financial engine is fueled by its diverse array of products and services, ranging from consumables like reagents and kits to sophisticated equipment for automating laboratory processes. Its diagnostic solutions are pivotal in areas like oncology, infectious diseases, and personalized medicine, enabling institutions to detect and analyze genetic information with precision. Additionally, Qiagen earns revenue by supporting pharmaceutical and biotech firms in their quest to discover and develop new drugs, ultimately contributing to safer, more effective treatments. The company also benefits from strategic collaborations and partnerships, continually expanding its influence and technological prowess. Through this multifaceted approach, Qiagen not only thrives in the competitive biotech landscape but also plays a critical role in transforming molecular data into actionable healthcare outcomes.

QGEN Intrinsic Value
43.72 USD
Overvaluation 3%
Intrinsic Value
Price

See Also

What is Qiagen NV's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
555.3m USD

Based on the financial report for Sep 30, 2024, Qiagen NV's Current Portion of Long-Term Debt amounts to 555.3m USD.

What is Qiagen NV's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
16%

Over the last year, the Current Portion of Long-Term Debt growth was 452%. The average annual Current Portion of Long-Term Debt growth rates for Qiagen NV have been 14% over the past three years , 50% over the past five years , and 16% over the past ten years .

Back to Top